Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

(2012) Samir E. Witta et al.   JOURNAL OF CLINICAL ONCOLOGY

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

Shock and kill

(2012) Steven G. Deeks   NATURE

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

(2012) Li Shen et al.   PLoS One

Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4)

(2012) I. Palmisano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIV Reservoirs and Strategies for Eradication

(2012) Miranda Z. Smith et al.   Current HIV/AIDS Reports

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

(2011) R Pili et al.   BRITISH JOURNAL OF CANCER

Belinostat: clinical applications in solid tumors and lymphoma

(2011) L Rhoda Molife et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

HDAC inhibitors in HIV

(2011) Fiona Wightman et al.   IMMUNOLOGY AND CELL BIOLOGY

Inhibitors of Histone Deacetylases

(2011) Kelly Huber et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation

(2011) S. Xing et al.   JOURNAL OF VIROLOGY

Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells

(2011) Suha Saleh et al.   Retrovirology

Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors

(2010) M. Ouaïssi et al.   CANCER BIOLOGY & THERAPY

The Histone Deacetylase Inhibitor ITF2357 Decreases Surface CXCR4 and CCR5 Expression on CD4+ T-Cells and Monocytes and is Superior to Valproic Acid for Latent HIV-1 Expression in Vitro

(2010) Shay Matalon et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Combinatorial Latency Reactivation for HIV-1 Subtypes and Variants

(2010) J. C. Burnett et al.   JOURNAL OF VIROLOGY

Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton

(2010) P. U. Cameron et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the epigenome: effects of epigenetic treatment strategies on genomic stability in healthy human cells

(2010) Jan C. Purrucker et al.   Clinical Epigenetics

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors

(2009) Nancie M Archin et al.   AIDS

Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid

(2009) Nancie M. Archin et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Pharmaceutical approaches to eradication of persistent HIV infection

(2009) Mary-Catherine Bowman et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells

(2009) Xavier Contreras et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Limited Group of Class I Histone Deacetylases Acts To Repress Human Immunodeficiency Virus Type 1 Expression

(2009) K. S. Keedy et al.   JOURNAL OF VIROLOGY

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE

"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence

(2009) Andrea Savarino et al.   Retrovirology

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

(2008) Nagma Khan et al.   BIOCHEMICAL JOURNAL

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

(2008) L. Gore et al.   CLINICAL CANCER RESEARCH

PP2A Regulates HDAC4 Nuclear Import

(2007) Gabriela Paroni et al.   MOLECULAR BIOLOGY OF THE CELL